Table 5. Changes in fibrosis stage among placebo treated patients in randomized trials.
| Author (year) | N | Treatment time (weeks) | Fibrosis Progressed (N) | Fibrosis Regressed (N) | Mean Fibrosis Change | Mean NAS Change |
|---|---|---|---|---|---|---|
| Harrison (2003)76 | 22 | 26 | 3 | 9 | -0.27 | -0.1 |
| Lindor (2004)77 | 57 | 104 | 12 | 12 | ||
| Belfort (2006)78 | 21 | 26 | 7 | -0.15 | -0.77 | |
| Dufour (2006)79 | 10 | 104 | 0.5 | |||
| Aithal (2008)80 | 30 | 52 | 6 | 6 | ||
| Ratziu (2008)81 | 31 | 52 | 6 | 5 | -0.18 | 0 |
| Abdelmalek (2009)82 | 28 | 52 | 0.4 | -1 | ||
| Haukeland (2009)83 | 24 | 26 | 4 | 0.08 | -0.42 | |
| Nelson (2009)84 | 6 | 52 | 0 | |||
| Leuschner (2010)85 | 91 | 78 | -0.08 | -1.03 | ||
| Promrat (2010)86 | 10 | 48 | -0.3 | -1.4 | ||
| Sanyal (2010)87 | 72 | 96 | 22 | -0.1 | -0.5 | |
| Lavine (2011)88 | 58 | 96 | 19 | -0.2 | -0.7 | |
| Van Wagner (2011)89 | 7 | 52 | 3 | 0 | 0.4 | -0.3 |
| Zein (2011)90 | 26 | 52 | 4 | 0.4 | -0.1 | |
| Wong (2013)91 | 20 | 24 | 5 | -0.1 | -0.3 | |
| Sanyal (2014)92 | 55 | 52 | 0 | -1 | ||
| Takeshita (2014)93 | 12 | 24 | 0 | -0.4 | ||
| Neuschwander-Tetri (2015)94 | 109 | 72 | 31 | 19 | 0.1 | -0.7 |
| Summary | 689 | 61/256 (24%) | 112/477 (23%) |